Drugs / SBI-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04445220 | Nov 2020 → Mar 2022 | COVID-19, acute kidney injury, infectious disease with sepsis | Sentien Biotechnologies, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03015623 | Jun 2017 → Dec 2021 | acute kidney injury | Sentien Biotechnologies, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SBI-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04445220 ↗ |
| Modality | Cell therapy | “allogeneic human mesenchymal stromal cells (MSCs)” NCT04445220 ↗ |
| Route | Other | “SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit” NCT03015623 ↗ |